Trial Profile
Phase II Study of Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma (HCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Oct 2020 Status changed from active, no longer recruiting to completed.
- 11 Nov 2019 Planned End Date changed from 1 Nov 2020 to 1 Nov 2022.
- 04 Sep 2019 Planned End Date changed from 1 Apr 2021 to 1 Nov 2020.